Regeneron (REGN +1.8%) gains on positive comments out of BMO Capital this morning, saying that...

|About: Regeneron Pharmaceuticals, ... (REGN)|By:, SA News Editor

Regeneron (REGN +1.8%) gains on positive comments out of BMO Capital this morning, saying that Roche's (RHHBY.PK +2.5%) Lucentis market share is declining, and the number of patients switching to Eylea from other treatments is accelerating. The firm maintains an Outperform rating on the stock.